Lyell Immunopharma, Inc.
(LYEL - NASDAQ)
15,43 USD
📋 Profilo Aziendale

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

|